Ara
Toplam kayıt 517, listelenen: 501-510
Modulatory therapy experience in patients with cystic fibrosis in Turkey: A multi-center study
(European Respiratory Society Journals Ltd., 2023)
Background: Modulatory therapies are not reimbursed in Turkey and approach to the treatment is currently available for three months only by court decision. In between the court decisions, most of the patients could not ...
Impact of SPARC expression on pembrolizumab treatment response and prognostic role in advanced stage non-small cell lung cancer
(Lippincott Williams & Wilkins, 2023)
...
KEYFORM-008: Coformulated favezelimab and pembrolizumab (MK4280A) versus chemotherapy in relapsed/refractory classical Hodgkin lymphoma.
(Lippincott Williams & Wilkins, 2023)
...
Long-term course of COVID-19 vaccination-related headache: A prospective multicenter follow-up study
(SAGE Publications Ltd, 2023)
...
Real-life experiences with galcanezumab disclosed new predictors for response
(SAGE Publications Ltd, 2023)
...
Vascular comorbidity and cognition in migraine
(SAGE Publications Ltd, 2023)
...
Idarubicin versus daunorubicin versus mitoxantrone for induction chemotherapy in acute myeloid leukemia: Patient registration study of Turkish society of hematologyacute myeloid leukemia working group
(American Society of Hematology, 2023)
Introduction: Standard induction chemotherapy in newly diagnosed acute myeloid leukemia (AML) includes a combination of standard-dose cytarabine and an anthracycline (idarubicin [IDA], daunorubicin [DNR], or mitoxantrone ...